prikaz prve stranice dokumenta Nove farmakoterapijske mogućnosti liječenja Alzheimerove bolesti
  Download
PDF 1.82 MB
master's thesis
Nove farmakoterapijske mogućnosti liječenja Alzheimerove bolesti
Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry, 2024. urn:nbn:hr:163:726042
Vicić, Klara
University of Zagreb
Faculty of Pharmacy and Biochemistry
Department of pharmacology

Institutional repository: Repository of Faculty of Pharmacy and Biochemistry University of Zagreb

Cite this document

Vicić, K. (2024). Nove farmakoterapijske mogućnosti liječenja Alzheimerove bolesti (Master's thesis). Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:726042

Vicić, Klara. "Nove farmakoterapijske mogućnosti liječenja Alzheimerove bolesti." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2024. https://urn.nsk.hr/urn:nbn:hr:163:726042

Vicić, Klara. "Nove farmakoterapijske mogućnosti liječenja Alzheimerove bolesti." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2024. https://urn.nsk.hr/urn:nbn:hr:163:726042

Vicić, K. (2024). 'Nove farmakoterapijske mogućnosti liječenja Alzheimerove bolesti', Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, accessed 06 October 2024, https://urn.nsk.hr/urn:nbn:hr:163:726042

Vicić K. Nove farmakoterapijske mogućnosti liječenja Alzheimerove bolesti [Master's thesis]. Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry; 2024 [cited 2024 October 06] Available at: https://urn.nsk.hr/urn:nbn:hr:163:726042

K. Vicić, "Nove farmakoterapijske mogućnosti liječenja Alzheimerove bolesti", Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, 2024. Available at: https://urn.nsk.hr/urn:nbn:hr:163:726042

Metadata
TitleNove farmakoterapijske mogućnosti liječenja Alzheimerove bolesti
Title (english)Novel pharmacotherapy possibilities for treatment of Alzheimer disease
AuthorKlara Vicić
MentorPetra Turčić (mentor)
Committee memberPetra Turčić (predsjednik povjerenstva)
Committee memberLidija Bach-Rojecky (član povjerenstva)
Committee memberDaniela Amidžić Klarić (član povjerenstva)
GranterUniversity of Zagreb
Faculty of Pharmacy and Biochemistry
(Department of pharmacology)
Zagreb
Defense date and country2024-07-18, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Pharmacy
Pharmacy
Abstract
Alzheimerova bolest (AD) je progresivna neurodegenerativna bolest koja uzrokuje značajan pad kognitivnih funkcija i kvalitete života oboljelih. Ovaj diplomski rad istražuje farmakoterapijske mogućnosti liječenja AD-a, uključujući postojeće i nove pristupe. Rad se fokusira na nekoliko ključnih aspekata: 1. Inhibitori acetilkolinesteraze: Donepezil, rivastigmin i galantamin su odobreni lijekovi koji djeluju povećanjem razine acetilkolina u mozgu, što može privremeno poboljšati ili stabilizirati simptome AD-a. 2. Antagonisti NMDA receptora: Memantin je lijek koji se koristi za liječenje umjerene do teške AD-a, djelujući na glutamatni sustav kako bi se smanjila neurotoksičnost. 3. Prirodni nootropici: Istraženi su prirodni spojevi poput ginka, ginsenga, bakope i kurkume, koji imaju potencijalne neuroprotektivne učinke. 4. Novija saznanja iz kliničkih studija: Proučeni su novi lijekovi poput adukanumaba, lekanemaba, donanemaba i AXS-05 koji ciljaju različite patofiziološke mehanizme AD-a, uključujući smanjenje amiloidnih plakova i upalnih procesa. Zaključno, unatoč trenutnom nedostatku lijeka koji bi mogao zaustaviti ili preokrenuti tijek AD-a, istraživanja u farmakoterapiji pružaju nadu za budućnost u smislu boljeg upravljanja simptomima i poboljšanja kvalitete života oboljelih. Potrebna su daljnja istraživanja kako bi se razvili učinkoviti tretmani koji bi ciljali temeljne uzroke bolesti.
Abstract (english)
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that significantly impairs cognitive functions and quality of life. This thesis explores the pharmacotherapeutic options for treating AD, including existing and emerging approaches. The study focuses on several key aspects: 1. Acetylcholinesterase inhibitors: Donepezil, rivastigmine, and galantamine are approved drugs that work by increasing acetylcholine levels in the brain, which can temporarily improve or stabilize AD symptoms. 2. NMDA receptor antagonists: Memantine is used for moderate to severe AD, acting on the glutamate system to reduce neurotoxicity. 3. Natural nootropics: Natural compounds such as ginkgo, ginseng, bacopa, and turmeric are explored for their potential neuroprotective effects. 4. Recent findings from clinical studies: New drugs like aducanumab, lecanemab, donanemab, and AXS-05 are studied, targeting various AD pathophysiological mechanisms, including reducing amyloid plaques and inflammatory processes. In conclusion, despite the current lack of a cure to halt or reverse AD progression, pharmacotherapy research offers hope for better symptom management and improved quality of life for patients. Further research is needed to develop effective treatments targeting the underlying causes of the disease.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:163:726042
Study programmeTitle: Pharmacy - integrated undergraduate and graduate - university study
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: sveučilišni magistar farmacije (sveučilišni magistar farmacije)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-09-26 12:33:35